Third time lucky for Roche in MAGE-A4?
The Swiss company is still interested in this antigen, after discontinuing two earlier clinical projects.
The Swiss company is still interested in this antigen, after discontinuing two earlier clinical projects.
April will see the first big scientific meeting of the year, and could herald important data from Immutep and GSK.
A roundup of the first quarter's key oncology drug approvals and rejections.
Not long after starting phase 1, RMC-6236 could be in pivotal trials this year.
Private company trial initiations stand out in the latest week’s disclosures.
As the biotech markets turned bullish the sector’s ups and downs continued.
Buoyed by the success of cadonilimab and ivonescimab the Chinese group takes two more bispecific MAbs into human trials.